[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
M Reinwald, JT Silva, NJ Mueller, J Fortún… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
[HTML][HTML] Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for
B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to …
B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to …
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
DM Stephens, JC Byrd - Blood, The Journal of the American …, 2019 - ashpublications.org
Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction
of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is …
of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is …
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial
Importance Oral targeted therapies have advanced the treatment of chronic lymphocytic
leukemia (CLL). These therapies include Bruton tyrosine kinase inhibitors, used as …
leukemia (CLL). These therapies include Bruton tyrosine kinase inhibitors, used as …
Management of adverse effects/toxicity of ibrutinib
S Paydas - Critical Reviews in Oncology/Hematology, 2019 - Elsevier
Bruton tyrosine kinase signaling (BTK) is critical step for B-cell development and
immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor …
immunoglobulin synthesis. Ibrutinib is an orally bioavailable bruton tyrosine kinase inhibitor …
[HTML][HTML] Targeting Bruton's tyrosine kinase in CLL
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective
for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas …
for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas …
[HTML][HTML] Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis
Introduction Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the
treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and …
treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and …
Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States
Purpose Oral targeted therapies represent a significant advance for the treatment of patients
with chronic lymphocytic leukemia (CLL); however, their high cost has raised concerns …
with chronic lymphocytic leukemia (CLL); however, their high cost has raised concerns …
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
J Klintman, N Appleby, B Stamatopoulos… - Blood, The Journal …, 2021 - ashpublications.org
The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is
known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we …
known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we …
Infectious complications of biological and small molecule targeted immunomodulatory therapies
The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …
immunosuppression. We have moved from relying on broadly active traditional medications …